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S U M M A R Y
Background: Traditional regimens for the treatment of brucellosis are associated with signiﬁcant relapse
rates. The aim of this study was to compare the efﬁcacy of oﬂoxacin plus rifampin (OFX–RIF) versus
doxycycline plus streptomycin (DOX–STR) and doxycycline plus rifampin (DOX–RIF) regimens in the
treatment of brucellosis.
Methods: Two hundred and nineteen patients with brucellosis were enrolled in a randomized clinical
trial; 28 cases were withdrawn because they did not attend the follow-up. Out of 191 patients with
brucellosis, 64 received OFX–RIF, 62 received DOX–RIF, and 65 patients received DOX–STR regimens. All
patients were assessed during the period of therapy in the second, fourth, and sixth weeks by clinical
course and were also followed up clinically and serologically for 6 months after the cessation of therapy.
Results: The highest clinical response (95.4%) was observed in the DOX–STR group (p = 0.009). The
results of multivariate analysis indicate that treatment with DOX–STR had the least therapeutic failures
among the three groups (p = 0.033). Adverse reactions were seen in 16.8% of patients, but there was no
signiﬁcant difference among the three groups (p = 0.613). The lowest relapse rate (4.6%) was observed in
the DOX–STR group (p = 0.109).
Conclusions: We conclude that the DOX–STR combination should remain the ﬁrst-line regimen for the
treatment of brucellosis in our region; we recommend DOX–RIF and OFX–RIF combinations as the
second-line regimens.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Brucellosis is a major zoonosis worldwide and represents a
serious public health problem, especially for the countries in the
Indian subcontinent, Arabian Peninsula, South Eastern Europe, and
Mediterranean Basin.1 The disease is endemic in Iran, with the
highest incidence rates of up to 130 per 100 000 population
reported from the western part of the country. Due to improved
efforts in the active immunization of young animals in recent
years, the incidence rate decreased to 45 per 100 000 in 2008 in
Hamedan, western Iran.2 However, the disease is still prevalent§ Registration ID in the Iranian Registry of Clinical trials is IRCT201101245681N1.
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doi:10.1016/j.ijid.2011.12.003among those in the economically active age groups, especially in
the rural population.
The goals of the treatment of brucellosis are to reduce
symptoms, length of disease, and complications, and to prevent
relapses. The use of appropriate antibiotic combinations is also
required for the successful treatment of brucellosis.
In addition to standard regimens for brucellosis, which include
doxycycline plus streptomycin or rifampin, a combination of one of
these drugs with ciproﬂoxacin has also been used in recent
years.3,4 However, a number of small clinical trials with combina-
tion regimens containing quinolones have shown adequacy, but
not superiority.5 The equal efﬁcacy and relapse rates of oﬂoxacin
plus rifampin and doxycycline plus rifampin have been reported in
a randomized clinical trial.6 In this study, we aimed to compare
the efﬁcacy, relapse rate, therapeutic failure rate, and adverse
effects of oﬂoxacin plus rifampin (OFX–RIF) versus doxycyclineses. Published by Elsevier Ltd. All rights reserved.
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Figure 1. Flow chart of patient recruitment and follow-up in this study.
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(DOX–RIF) regimens in the treatment of brucellosis.
2. Materials and methods
2.1. Study design
A prospective randomized clinical trial with repeated measure-
ments was carried out. From April 2008 to March 2010, 219
patients with brucellosis who were referred to Sina Hospital as
outpatients or inpatients were enrolled in this study. Sina Hospital
is the main referral center for infectious diseases in Hamedan
Province in the west of Iran.
Exclusion criteria were deﬁned age under 17 years, endocardi-
tis, neurobrucellosis, spondylitis, renal failure, hepatic failure, or a
history of treatment for brucellosis in the last 6 months.
2.2. Diagnosis of brucellosis
Brucellosis was diagnosed based on clinical presentation
compatible with brucellosis in the presence of signiﬁcant titers
of speciﬁc antibodies (standard tube agglutination 1/160,
Coombs test 1/160, 2-mercaptoetanol (2-ME) 1-80, or Brucella
IgG-ELISA >12) and/or a positive blood culture. ELISA for Brucella
IgG was performed using a speciﬁc kit (IBL, Hamburg, Germany),
and the antigens for other serologic tests were obtained from the
Pasteur Institute, Iran.
2.3. Randomization, treatment, and follow-up
According to the results of previous studies, we considered the
efﬁcacy rate of the DOX–STR regimen to be 90–95% and for the
DOX–RIF and OFX–RIF regimens to be 75–85%. Based on a
conﬁdence interval of 95% (a = 0.05) and a power calculation of
80% (b = 20%), the sample size required for each group was
estimated to be 73 cases. In this study, 246 patients were assessed
for eligibility and 27 cases were excluded because they did not
meet the inclusion criteria or declined to participate. Therefore, on
the basis of a random numbers table, 219 prepared questionnaires
were divided into the three antimicrobial therapy groups and thepatients were enrolled into the study in questionnaire number
order. Twenty-eight patients did not attend the ﬁrst follow-up
examinations and so were excluded at the beginning of the study
(Figure 1). Finally, 65 patients in the DOX–STR group received
doxycycline 200 mg daily for 6 weeks plus streptomycin 1000 mg
daily for the ﬁrst 3 weeks; 62 patients in the DOX–RIF group were
treated with doxycycline 200 mg daily plus rifampin 15 mg/kg
daily for 6 weeks; and 64 patients in the OFX–RIF group received
oﬂoxacin 800 mg daily plus rifampin 15 mg/kg daily for 6 weeks.
The study was approved by the Research Committee of Hamedan
University of Medical Sciences.
After obtaining informed consent, a detailed medical history
was taken from each patient and a complete physical examination
was performed. The information was recorded in the question-
naires.
2.4. Deﬁnitions
Primary outcomes were evaluated by measuring clinical response
rates and therapeutic failure rates. Secondary outcomes were
evaluated by measuring relapse rates and adverse reaction rates.
Clinical response was deﬁned as clinical improvement of
primary signs (objective) and symptoms (subjective) of disease at
the end of treatment recorded apart for each patient. Therapeutic
failure was deﬁned as the persistence of symptoms and signs at the
end of 6 weeks of therapy. Relapse was deﬁned as the reappearance
of symptoms and signs accompanied by a 2-ME titer 1/80 during
the follow-up period.
2.5. Follow-up
All patients were assessed in the second, fourth, and sixth
weeks of therapy by clinical course. They were also followed-up
clinically and serologically for 6 months after the cessation of
therapy.
2.6. Statistical analysis
Data were analyzed using SPSS statistical package, version 15.
The analysis of variance (ANOVA) test was used for quantitative
Table 1
Demographic and clinical characteristics of 191 patients with brucellosis in the three therapy groups
Characteristic Oﬂoxacin–rifampin (n = 64) Doxycycline–rifampin (n = 62) Doxycycline–streptomycin (n = 65) p-Value
Age (years), mean  SD 40.5  14.2 38.6  17.3 39.9  15.4 0.797
Gender, female/male 28/36 28/34 29/36 0.987
Living, rural 27 (42.2%) 24 (38.7%) 22 (33.8%) 0.364
Duration of symptoms (days), mean  SD 60.1  103 68.6  150.9 46.6  34.3 0.573
Fever 17 (26.6%) 16 (25.8%) 23 (35.4%) 0.415
Anorexia 24 (37.5%) 29 (46.8%) 33 (50.8%) 0.300
Sweating 36 (56.3%) 23 (37.1%) 35 (53.8%) 0.065
Weight loss 14 (21.9%) 14 (22.6%) 19 (29.2%) 0.564
Headache 31 (48.4%) 29 (46.8%) 29 (44.6%) 0.218
Low back pain 43 (67.2%) 40 (64.5%) 47 (72.3%) 0.631
Arthralgia 46 (71.9%) 46 (74.2%) 50 (76.9%) 0.806
Body ache 38 (59.4%) 34 (54.8%) 38 (58.5%) 0.862
Fatigue 45 (70.3%) 43 (69.4%) 53 (81.5%) 0.218
Splenomegaly 10 (15.6%) 5 (8.1%) 10 (15.4%) 0.352
Arthritis 7 (10.9%) 16 (25.8%) 10 (15.4%) 0.077
Orchitis (males) 6/36 (16.7%) 2/34 (5.9%) 1/36 (2.8%) 0.086
SD, standard deviation.
Table 3
Multivariate analyses for different events in patients with brucellosis according to
selected characteristics among the three therapy groups
Event p-Value OR (95% CI)
Clinical improvement
Doxycycline–streptomycin
Oﬂoxacin–rifampin 0.923 0.922 (0.178–4.788)
Doxycycline–rifampin 0.035 0.233 (0.060–0.902)
Age in years 0.167 0.978 (0.947–1.009)
Male sex 0.930 0.954 (0.329–2.768)
Therapeutic failure
Doxycycline–streptomycin
Oﬂoxacin–rifampin 0.619 1.482 (0.314–6.986)
Doxycycline–rifampin 0.033 4.398 (1.128–17.144)
Age in years 0.078 1.029 (0.997–1.063)
Male sex 0.939 0.960 (0.341–2.700)
Adverse reactions
Doxycycline–streptomycin
Oﬂoxacin–rifampin 0.980 0.988 (0.395–2.474)
Doxycycline–rifampin 0.386 0.648 (0.242–1.730)
Age in years 0.117 1.020 (0.995–1.046)
Male sex 0.908 0.955 (0.435–2.095)
Relapse
Doxycycline–streptomycin
Oﬂoxacin–rifampin 0.393 1.912 (0.433–8.452)
Doxycycline–rifampin 0.067 3.598 (0.915–14.148)
Age in years 0.238 0.980 (0.948–1.013)
Male sex 0.452 0.085 (0.520–4.346)
OR, odds ratio; CI, conﬁdence interval.
Table 2
Primary and secondary outcomes of brucellosis with the three therapy regimens
Characteristic Oﬂoxacin–rifampin (n = 64) Doxycycline–rifampin (n = 62) Doxycycline–streptomycin (n = 65) p-Value
Clinical response 60 (93.8%) 52 (83.9%) 62 (95.4%) 0.009
Therapeutic failure 4 (6.3%) 10 (16.1%) 3 (4.6%) 0.036
Adverse reactions 12 (18.8%) 8 (12.9%) 12 (18.5%) 0.613
Relapse 5 (7.8%) 9 (15.3%)a 3 (4.6%) 0.109
a After the cessation of therapy, 59 patients underwent the 6-month follow-up.
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regression for multivariate analysis. A sensitivity analysis was
conducted to investigate the best and the worst case scenarios in
this study to reduce the risk of bias. In the best case scenario, it was
assumed that all patients excluded had a good response to
treatment, and in the worst case scenario, it was assumed that all
patients excluded did not respond to treatment, for all three
treatment groups. Differences with a p-value of <0.05 were
considered statistically signiﬁcant.
3. Results
Of the 191 patients with brucellosis, 64 received OFX–RIF, 62
received DOX–RIF, and 65 received DOX–STR regimens. There were
no signiﬁcant differences in the demographic and clinical
characteristics and laboratory ﬁndings among the three groups
(Table 1). The most common symptoms and signs included
arthralgia (74.3%), fatigue (73.8%), low back pain (68.1%), body
ache (57.6%), sweating (49.2%), headache (46.6%), and anorexia
(45.0%). Brucella melitensis was isolated from three of 12 patients
for whom blood cultures were obtained.
The primary and secondary outcomes of the disease in the three
treatment groups are shown in Table 2. After 6 weeks of therapy,
the highest clinical response was observed in the DOX–STR group
(95.4%), in whom the symptoms including body ache, fatigue,
sweating, and low back pain were signiﬁcantly relieved. However,
the sensitivity analysis for clinical response based on the worst and
the best case scenarios showed that there were no signiﬁcant
differences among the three treatment groups (p = 0.095 and
p = 0.064, respectively).
Therapeutic failure was observed in 8.9% of all patients. The
DOX–RIF group showed the highest rate of failure (16.1%), and the
lowest rate was observed in the DOX–STR group (4.6%). Logistic
regression analysis was used to estimate differences among the
three therapy groups based on selected characteristics; results are
show in Table 3. The results of multivariate analysis indicate thattreatment with DOX–STR had the least therapeutic failures among
the three groups (p = 0.033). Adverse reactions were seen in 16.8%
of patients, and there were no signiﬁcant differences among the
three groups (Table 4). Most of the adverse effects were classiﬁed
as mild; therefore, these reactions were not severe enough to
discontinue therapy. Of the 191 patients, 188 underwent 6 months
of follow-up; three patients did not attend these follow-up
examinations after the cessation of therapy. Relapse was observed
in 9.0% of all patients. The lowest relapse rate was observed in the
Table 4
Frequency of adverse reactions among patients with brucellosis in the three therapy
groupsa
Adverse reactions Oﬂoxacin–
rifampin
(n = 64)
Doxycycline–
rifampin
(n = 62)
Doxycycline–
streptomycin
(n = 65)
Photosensitivity - - 2
Epigastric pain 6 3 2
Nausea or vomiting 1 2 1
Diarrhea 2 - -
Heartburn 1 - -
Dizziness 2 - 2
Rash 1 1 1
Circumoral paresthesia 1 1 5
Urticaria 1 1 -
Total 15 8 13
a Some patients had more than one adverse effect. A total of 12 patients (18.8%) in
the oﬂoxacin–rifampin group, eight patients (12.9%) in the doxycycline–rifampin
group, and 12 patients (18.5%) in the doxycycline–streptomycin group had adverse
reactions. No statistically signiﬁcant differences among groups were found.
S.H. Hashemi et al. / International Journal of Infectious Diseases 16 (2012) e247–e251e250DOX–STR group (4.6%) and the highest in the DOX-RIF group
(15.3%), although the difference was not signiﬁcant.
4. Discussion
In the present study, the highest clinical response rate and the
lowest therapeutic failure rate were observed with the DOX–STR
regimen, while the lowest clinical response rate and the highest
therapeutic failure and relapse rates were seen in the DOX–RIF
group. According to the results, the OFX–RIF regimen showed more
efﬁcacy than the DOX–RIF regimen. However, some clinical trials
with combination regimens containing quinolones such as OFX–
RIF have shown adequacy, but not superiority.5,6 The superiority of
the DOX–STR regimen has been reported in various studies, hence
some authorities recommend the use of DOX–STR as the regimen
of choice for the treatment of brucellosis.7,8 Nevertheless, there is
no general agreement on the most appropriate regimen.
In 1986, the World Health Organization proposed the two
antibiotic combinations DOX–RIF and DOX–STR as standard
therapeutic regimens for brucellosis.9 DOX–RIF was noted as the
preferred choice due to the cheaper cost and the oral administra-
tion of the drugs. In the last two decades, several studies have
indicated the equal efﬁcacy of the two regimens; however, the
DOX–STR regimen has been regarded as the therapy of choice for
the treatment of osteoarticular complications of brucellosis.10,11
Nevertheless, these regimens are still accompanied by 5–15%
relapse rates.11,12 A long duration of therapy decreases the risk of
relapse. However, the prolonged use of rifampin may increase the
potential risk for the emergence of tuberculosis in endemic areas,
such as our region, in which both brucellosis and tuberculosis are
endemic.13
In a systemic review and meta-analysis of randomized
controlled trials in 2008, the authors concluded that the DOX–
RIF regimen is accompanied by more therapeutic failures than the
DOX–STR regimen.14 They also concluded that the combination of
a quinolone with rifampin is less effective than the DOX–RIF or
DOX–STR combinations.
Besides the superior efﬁcacy of the DOX–STR regimen, our
study also indicates the higher therapeutic failure and relapse rates
of the OFX–RIF than the DOX–STR regimen. Moreover, in a recent
clinical trial, we reported a high relapse rate of quinolone-
containing regimens, including ciproﬂoxacin–rifampin and cipro-
ﬂoxacin–doxycycline.15 According to our results and those of other
studies indicating the emergence of quinolone resistance, we
recommend the use of ﬂuoroquinolone-containing regimens onlyas alternative regimens and not as the ﬁrst choice for the treatment
of brucellosis.
Of note is the prominence of B. melitensis in our region and
many other endemic areas, which is the most virulent species and
commonly results in complications with osteoarticular involve-
ment.16 The consensus of most researchers that aminoglycoside-
containing regimens such as DOX–STR are preferred for compli-
cated brucellosis is in accordance with the brucellosis situation in
our region, and may be explained by the reported superiority of
DOX–STR in our results and those of other studies that have been
conducted in our region and in other developing countries.17–19
Our study had some limitations. The study was not double-
blind and the patients were not followed-up for more than 6
months. In addition, because the patients were ambulatory, we did
not perform blood cultures for all patients. Another limitation was
the scarcity of fever in our cases, so we were not able to include
fever as a criterion for clinical response in the follow-up of the
patients. Another noticeable point in our study was the exclusion
of patients with special forms of localized brucellosis including
endocarditis, spondylitis, and neurobrucellosis. Therefore, we
recommend more research regarding the treatment of these
complications.
According to the results of the worst and the best case scenarios
in our study, there were no signiﬁcant differences among the three
regimen groups, so we recommend more research on these
regimens.
In conclusion, the DOX–STR combination should remain the
ﬁrst-line regimen for the treatment of brucellosis in our region; we
recommend the DOX–RIF and OFX–RIF combinations as the
second-line regimens.
Acknowledgements
This study was supported in part by the Vice-Chancellor of
Research and Technology, Hamedan University of Medical
Sciences, Hamedan, Iran. The contributions of L. Gachkar were
supported by a fund from the Research Center for Infectious
Diseases, Shahid Beheshti University of Medical Sciences, Tehran,
Iran (grant No. A-G-991).
Ethical approval: The study was approved by the ethics
committee of Hamedan University of Medical Sciences and
subjects gave informed consent to participate.
Conﬂict of interest: None declared.
References
1. Donev DM. Brucellosis as priority public health challenge in south eastern
European countries. Croat Med J 2010;51:283–4.
2. Moradi A, Norouzi NA, Talebi B, Erfani H, Karimi A, Bathaei SJ, et al. Evaluation of
animal vaccination against brucellosis on human incidence rate in Hamedan
Province 2002–2008. J Hamedan Univ Med Sci 2009;16:44–8.
3. Pappas G, Akritidis N, Bosilkovski M, Tsianos E. Brucellosis. N Engl J Med
2005;352:2325–36.
4. Ersoy Y, Sonmez E, Tevﬁk MR, But AD. Comparison of three different combina-
tion therapies in the treatment of human brucellosis. Trop Doct 2005;35:210–2.
5. Pappas G, Christou L, Akritidis N, Tsianos EV. Quinolones for brucellosis:
treating old diseases with new drugs. Clin Microbiol Infect 2006;12:823–5.
6. Karabay O, Sencan I, Kayas D, S¸ahin I. Oﬂoxacin plus rifampicin versus doxycy-
cline plus rifampicin in the treatment of brucellosis: a randomized clinical trial.
BMC Infect Dis 2004;4:18.
7. Solera J. Treatment of human brucellosis. J Med Liban 2000;48:255–63.
8. Buzgan T, Karahocagil MK, Irmak H, Baran AI, Karsen H, Evirgen O, et al. Clinical
manifestations and complications in 1028 cases of brucellosis: a retrospective
evaluation and review of the literature. Int J Infect Dis 2010;14:e469–78.
9. Joint FAO/WHO expert committee on brucellosis. World Health Organ Tech Rep
Ser 1986;740:1–132.
10. Ariza J, Bosilkovski M, Cascio A, Colmenero JD, Corbel MJ, Falagas ME, et al.
Perspectives for the treatment of brucellosis in the 21st century: the Ioannina
recommendations. PLoS Med 2007;4:1872–8.
11. Solera J, Martinez-Alfaro E, Espinosa A, Castillejos ML, Geijo P, Rodrı´guez-Zapata
M. Multivariate model for predicting relapses in human brucellosis. J Infect
1998;36:85–92.
S.H. Hashemi et al. / International Journal of Infectious Diseases 16 (2012) e247–e251 e25112. Ariza J, Corredoira J, Pallares R, Viladrich PF, Ruﬁ G, Pujol M, et al. Characteristics
of and risk factors for relapse of brucellosis in humans. Clin Infect Dis
1995;20:1241–9.
13. Al-Hajjaj MS, Al-Kassimi FA, Al-Mobeireek AF, Alzeer AH. Progressive rise of
Mycobacterium tuberculosis resistance to rifampicin and streptomycin in
Riyadh, Saudi Arabia. Respirology 2001;6:317–22.
14. Skalsky K, Yahav D, Bishara J, Pitlik S, Leibovici L, Paul M. Treatment of human
brucellosis: systematic review and meta-analysis of randomised controlled
trials. BMJ 2008;336:701–4.
15. Keramat F, Ranjbar M, Mamani M, Hashemi SH, Zeraati F. A comparative trial of
three therapeutic regimens: ciproﬂoxacin–rifampin, ciproﬂoxacin–doxycyclineand doxycycline–rifampin in the treatment of brucellosis. Trop Doct 2009;39:
207–10.
16. Zowghi E, Ebadi A, Yarahmadi M. Isolation and identiﬁcation of Brucella
organisms in Iran. Iranian J Clin Infect Dis 2008;3:185–8.
17. Hashemi SH, Keramat F, Ranjbar M, Mamani M, Farzam A, Jamal-Omidi S.
Osteoarticular complications of brucellosis in Hamedan, an endemic area in the
west of Iran. Int J Infect Dis 2007;11:496–500.
18. Roushan MR, Baiani M, Javanian M, Kasaeian AA. Brucellar epididymo-orchitis:
review of 53 cases in Babol, northern Iran. Scand J Infect Dis 2009;41:440–4.
19. Al-Tawﬁq JA. Therapeutic options for human brucellosis. Expert Rev Anti Infect
Ther 2008;6:109–20.
